Loss of ARID1A was reported to be associated with increasing TMB, TILs, and PD-L1 expression in ovarian clear cell carcinoma and gastric carcinoma (23–25), and patients with ARID1A deficiency had a higher response rate to immunotherapy (26). This evidence concerns the gene ARID1A and gastric carcinoma.